1224 related articles for article (PubMed ID: 12637119)
21. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
22. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
Weyer G; Babej-Dölle RM; Hadler D; Hofmann S; Herrmann WM
Neuropsychobiology; 1997; 36(2):73-82. PubMed ID: 9267856
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
24. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
[TBL] [Abstract][Full Text] [Related]
25. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
26. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
27. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
28. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.
Kanowski S; Hoerr R
Pharmacopsychiatry; 2003 Nov; 36(6):297-303. PubMed ID: 14663654
[TBL] [Abstract][Full Text] [Related]
29. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
31. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
32. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
[TBL] [Abstract][Full Text] [Related]
33. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
34. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
35. Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M; Grimley EJ; Areosa SA
Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
[TBL] [Abstract][Full Text] [Related]
38. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
39. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
Stein MS; Scherer SC; Ladd KS; Harrison LC
J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]